Xsulin 100IU Pen contains human insulin at a concentration of 100 international units per milliliter, designed for subcutaneous administration to manage blood glucose levels in patients with diabetes mellitus. This rapid-acting insulin analog mimics endogenous insulin activity, facilitating cellular glucose uptake and utilization, thereby reducing hyperglycemia. The pen device offers precise dosing with ease of use, enhancing patient compliance and allowing flexible insulin therapy tailored to individual glycemic control needs. Xsulin 100IU Pen is indicated for the treatment of type 1 diabetes mellitus, type 2 diabetes mellitus when oral hypoglycemic agents are insufficient, and for diabetic ketoacidosis management. It should be administered according to a healthcare professional’s guidance, with dose adjustments based on blood glucose monitoring, dietary intake, and physical activity. Patients must be educated on proper injection techniques, storage conditions, and recognition of hypoglycemia symptoms. Contraindications include hypersensitivity to human insulin or any excipients. Caution is advised in patients with renal or hepatic impairment. Adverse effects may include hypoglycemia, injection site reactions, and rare allergic responses. Regular monitoring and adherence to prescribed regimens are essential to optimize therapeutic outcomes and minimize risks associated with insulin therapy.